Stock 301263 GUANGDONG TAIENKANG PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Guangdong Taienkang Pharmaceutical Co., Ltd.

Equities

301263

CNE1000058X0

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
12.99 CNY +2.93% Intraday chart for Guangdong Taienkang Pharmaceutical Co., Ltd. -4.70% -20.45%
Apr. 22 Guangdong Taienkang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 22 Guangdong Taienkang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Guangdong Taienkang Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023
CI
Guangdong Taienkang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Guangdong Taienkang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tranche Update on Guangdong Taienkang Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 31, 2023.
CI
Tranche Update on Guangdong Taienkang Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 31, 2023.
CI
Guangdong Taienkang Pharmaceutical Co., Ltd announces an Equity Buyback for CNY 50 million worth of its shares.
CI
Guangdong Taienkang Pharmaceutical Co., Ltd authorizes a Buyback Plan.
CI
Guangdong Taienkang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Guangdong Taienkang Pharmaceutical Co., Ltd(XSEC:301263) added to S&P Global BMI Index
CI
BCY Pharm Co., Ltd. announced that it has received CNY 150 million in funding from Guangdong Taienkang Pharmaceutical Co., Ltd
CI
Guangdong Taienkang Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
CI
BCY Pharm Co., Ltd. announced that it expects to receive CNY 150 million in funding from Guangdong Taienkang Pharmaceutical Co., Ltd
CI
Guangdong Taienkang Pharmaceutical Co., Ltd Approves Cash Dividend on A Shares for the Year 2022, Payable on 29 May 2023
CI
Guangdong Taienkang Pharmaceutical Co., Ltd Proposes Final Cash Dividend for 2022
CI
Guangdong Taienkang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Guangdong Taienkang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Certain A Shares of Guangdong Taienkang Pharmaceutical Co., Ltd are subject to a Lock-Up Agreement Ending on 30-MAR-2023.
CI
Taienkang Pharma to Buy 50% of Local Biomedical Firm For 200 Million Yuan
MT
Guangdong Taienkang Pharma to Buy 50% of Local Biomedical Firm For 200 Million Yuan
MT
Guangdong Taienkang Pharmaceutical Co., Ltd entered into an investment agreement to acquire BCY Pharm Co., Ltd from Nanjing Baijiahui Biotechnology Development Co., Ltd and others for CNY 200 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 301263 Stock
  4. News Guangdong Taienkang Pharmaceutical Co., Ltd.